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BACKGROUND: Althoughpazopanib treatment hasbecome the standard chemotherapy in salvage setting formetastatic
sarcoma patients, most patients progress after pazopanib treatment in 4 to 6months. After failure to pazopanib, patients
have limited options for treatment. Therefore, subsequent therapy in patients who failed to pazopanib is urgently needed
and the use of patient derived cells or patient derived tumors for accompanying testing with various pharmacological
inhibitors could offer additional treatment options for these patients. METHODS: Patient derived tumor cells were
collected from ascites at the time of progression to pazopanib and a 13-drug panel was tested for drug sensitivity. We
confirmed the results using in vitro cell viability assay and immunoblot assay.We also performed the genomic profiling of
PDX model. RESULTS: The growth of patient derived tumor cells was significantly reduced by exposure to 1.0 μM
AZD2014 compared with control (control versus AZD2014, mean growth = 100.0% vs 16.04%, difference = 83.96%,
95% CI = 70.01% to 97.92%, P= .0435). Similarly, 1.0 μMBEZ235 profoundly inhibited tumor cell growth in vitrowhen
compared to control (control versusBEZ235,meangrowth=100.0%vs7.308%,difference=92.69%,95%CI=78.87%
to 106.5%, P b .0001). Despite the presence of CDK4 amplification in the patient-derived tumor cells, LEE011 did not
considerably inhibit cell proliferationwhen comparedwith control (control vs LEE011,meangrowth=100.0%vs 80.23%,
difference= 19.77%, 95%CI=1.828% to 37.72%, P= .0377). The immunoblot analysis showed that BEZ235 treatment
decreased pAKT, pmTOR and pERK whereas AZD2014 decreased only pmTOR. CONCLUSION: Taken together,
upregulation of mTOR/AKT pathway in sarcoma patient derived cells was considerably inhibited by the treatment of
AZD2014 and BEZ235 with downregulation of AKT pathway (greater extent for BEZ235). These molecules may be
considered as treatment option in STS patient who have failed to pazopanib in the context of clinical trials.
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Soft tissue sarcomas (STS) comprise a heterogeneous group of
malignant neoplasms which are derived from mesenchymal origin.
STS can be located anywhere in the human body. There are more
than 50 different sub-types according to the recent revised WHO
classification [1,2]. The incidence of STS is low accounting for
approximately 1% of adult cancers worldwide [3]. Approximately
10,000 and 3,300 newly diagnosed cases are reported annually in the
USA and the UK, respectively [4,5]. In patients with localized disease,
surgical resection with or without radiotherapy and chemotherapy is
the preferred therapeutic approach and the estimated 5-year survival
rate is about 70% [6,7]. STS recur frequently as locally inoperable or
metastatic disease and systemic therapy has a prominent role in the
multidisciplinary management in this setting [6]. However, patients
with metastatic disease have an estimated 3-year survival rate of 20%
to 45% [7]. It is of note that there has been no significant
improvement in the survival rate of patients with metastatic disease
over the last few years despite the continuous development of
systemic therapy regimens in the first-line setting [8–10]. Although
toxicity and resistance appear to be the major drawbacks associated
with systemic therapy in the first-line setting, it should be noted that
there have been no robust data regarding the use of systemic therapy
in the second-line setting [11]. Thus, there is unmet clinical need for
the treatment of patients with advanced STS in both the first- and the
second-line settings. In our previous report on 43 patients treated
with pazopanib as salvage treatment, the overall response rate was
17.1% and PFS was 5.0 months (95% CI, 3.6 to 6.4 months) [12].
Therefore, subsequent therapy in patients who failed to pazopanib is
urgently needed. Few reports have reported on the potential efficacy
of phosphatidylinositol-3 kinase inhibitors (PIK3) in sarcoma
preclinical models [13–16]. The use of patient-derived xenografts
(PDX) for advanced sarcoma has also been described [17].
Herein we report the case of a patient with refractory
undifferentiated pleomorphic sarcoma and the potential of
BEZ235, a PIK3/mTOR inhibitor, after failing to pazopanib in a
patient-derived tumor model established from tumor material after
failed first-line therapy with pazopanib.
Methods
Written Informed Consent
The patient was enrolled as part of the SMC Oncology Biomarker
study (NCT#01831609, clinicaltrials.gov) [18], which is reported
elsewhere. Effusions were obtained for therapeutic purposes after
obtaining written informed consent, and all procedures were carried
out according to guidelines from the Declaration of Helsinki. The
Institutional Review Board at the Samsung Medical Center approved
the protocol.
Patient-Derived Cell Culture and Reagents
Malignant ascites were collected after signature of the informed
consent form. Collected effusions (1 to 5 L) were divided into 50-mL
tubes, centrifuged at 1500 rpm for 10 min, and washed twice with
PBS as previously described [18]. Extracted cells were cultured in
RPMI media supplemented with 10% fetal bovine serum, 0.5 g/ml of
hydrocortisone (Sigma Aldrich), 5 g/ml of insulin (PeproTech,
Rocky Hill, NJ, USA), 5 ng of EGF and FGF (PeproTech). BEZ235,
AZD2014, lapatinib, LEE011 and pazopanib were purchased
from Selleck Chemical (Houston, TX, USA). After pathologicconfirmation, cells were seeded at 1 × 106 cells/10 mm dishes or
5000 cells/well/96well plate and treated with 1 μM of each
inhibitor after passage #2. Treated cells were incubated for 72
hours at 37°C in a humidified atmosphere of 5 % carbon dioxide.
Inhibition of tumor derived cell line proliferation was determined
using CellTiter-Glo® (Promega, Madison, WI, USA) according to the
manufacturer’s protocol.
For 3-dimensional drug screening system, we utilized the S+ Chip
Analyzer (Samsung Electro-Mechanics Co., Ltd, South Korea) to
analyze the image of the cells grown in 3D droplets on micropillars as
previously described [19]. Briefly Cultured primary patient derived
cells (passage 1 to 4, 2D) were seeded into 3D culture media; DMEM
F/12 containing 1% antibiotic-anti-mycotic solution, 10 mM of
HEPES, B27, N2, Glutamax (Gibco BRL), 1 mM of N-acetyl-L-
cysteine (Sigma Aldrich), 10 μg/ml of insulin (PeproTech, Rocky
Hill, NJ, USA), 20 ng/ml of bFGF, and 50 ng/ml of EGF
(PeproTech). After 3 to 5 days, the organoids were dissociated by
using accutase (Gibco BRL) to the single cells and prepared to load on
the micropillar chip. 40 nl droplet for cell/alginate mixture and 950 nl
for media or compounds were dispensed with S+ microarrayer (S+
Chip Scanner, Samsung Electro-Mechanics Co., Ltd, South Korea).
After 1 day incubation, the micropillar chip containing cells moves to
new microwell chip filled with various test compounds and combined
chips are incubated during 7 days for compound efficacy test as
shown in previously published method [20].
PDX Models Established from PDCs
PDCs were transferred to Oncotest as frozen vials. On site, the cells
were thawed, the freezing medium was removed, and the cells were
resuspended and transferred into T75 flasks. Cells were grown for 3 to
7 days in RPMI/10% FBS until the culture reached around 80%
confluence. Cells were collected and counted, and 5 × 106 cells were
injected into the hind flanks of NOD scid gamma (NOG) mice
(Taconic). Tumors developed within 25 to 85 days after injection;
these tumors were explanted, and viable portions of the tumors were
cut into pieces and implanted subcutaneously into female NMRI nu/
nu mice (Harlan Laboratories). This process was repeated in order to
serially passage the respective models. From each passage, forma-
lin-fixed, paraffin-embedded (FFPE) blocks were prepared, and
tumor slices were stained with hematoxylin and eosin (H&E). Slides
were scanned with a Hamamatsu slide scanner, and images were
extracted using the Nanozoomer program from Hamamatsu. All
animal handling and experiments with animals were in accordance
with the guidelines set by the Samsung Biological Research Institute.
Western Blot Analyses
Total proteins from PDCs were isolated using RIPA buffer
(Sigma-Aldrich) containing a protease inhibitor cocktail (Roche,
Mannheim, Germany) and phosphatase inhibitor cocktail (Roche),
and protein concentrations were determined according to the
Bradford procedure using a Quick Start Bradford Protein Assay
(Bio-Rad, Hercules, CA, USA). Thirty micrograms of proteins were
subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis on 10% gels and then electrotransferred to nitrocel-
lulose membranes incubated with the following specific antibodies:
Cyclin D1 (sc-718) (M-20) from Santa Cruz (USA) and PI3K
(#4255) (p110α), phospho-mTOR (#2971) (Ser2448), mTOR
(#2983) (7C10), phospho-Akt (#4060) (Ser473), Akt (#9272),
phospho-ERK1/2 (#4370) (Thr202/Tyr204), ERK1/2 (#9102) from
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peroxidase-conjugated anti-rabbit or mouse IgG (Vector, Burlin-
game, CA, USA) was used as a secondary antibody, and signals were
detected by chemiluminescence using ECL Western Blotting
Substrate (Thermo Scientific, Rockford, IL, USA).
Targeted Sequencing
Genomic DNA from single cell suspensions of PDX tumors were
extracted, and a SureSelect customized kit (Agilent Technologies,
Santa Clara, CA, USA) was used for capturing 381 cancer-related
genes. Illumina HiSeq 2500 was used for sequencing with 100 bp
paired-end reads. The sequencing reads were aligned to the human
genome reference sequence (hg19) using BWA-mem (v0.7.5),
SAMTOOLS (v0.1.18), Picard (v1.93), and GATK (v3.1.1) for
sorting SAM/BAM files, duplicate marking, and local realignment.
Local realignment and base recalibration were carried out based on
dbSNP137, Mills indels, HapMap, and Omni. SNVs and InDels
were identified using Mutect (v1.1.4) and Pindel (v0.2.4),
respectively. ANNOVAR was used to annotate the detected variants.
Copy number variations (CNVs) were called by an in-house
algorithm. The module ‘Depth of Coverage’ in GATK v3.1-1 was
used to calculate sequencing coverage in each exon. The median
values of mean coverage for total exons were calculated and divided by
the respective gained average. The median value of each exon in
normal reference datasets was used as a reference value. Then the
normalized median value of exons of each patient was divided by the
reference value and transformed to the binary logarithm.
Statistical Method
For PDC viability curves, results are expressed as the means. Paired
one way ANOVA tests were used to calculate the P values. Statistical
significance was assessed using one way ANOVA tests and described
in the figure.
Results
Patient History
A 56-year-old woman presented with abdominal pain in May
2012, with a computed tomography (CT) scan showing a huge
retroperitoneal mass. She was diagnosed with a retroperitoneal French
Fédération Nationale des Centres de Lutte Contre le Cancer
(FNCLCC) grade 3 undifferentiated pleomorphic sarcoma after
palliative surgical excision of tumor. She achieved partial remission
initially with VAC/IE (vincristine, adriamycin, cyclophosphamide,Figure 1. The CT evaluation of the patient during the coursifosfamide, etoposide), but a new cystic retroperitoneal mass and
right-sided hydronephrosis appeared on the follow-up CT scan in
January 2013 after the 7th treatment-cycle. She underwent second
surgery to extirpate the recurrent mass. After the second operation,
she had rapidly progressive disease on 2 cycles of gemcitabine/
docetaxel and 2 cycles of VIP (vincristine, ifosfamide, cisplatin). After
2 weeks of treatment with pazopanib, a CT scan demonstrated
hemorrhagic necrosis of tumor and her abdominal pain was
substantially decreased. After 6 weeks on pazopanib, the patient
had progressive disease with newly developed ascites (Figure 1, right
panel). At this time, the patient derived tumor cells from ascites were
collected and cultured. After stopping pazopanib, the patient was on
supportive care until her death due to disease progression.
Patient Derived Sarcoma Cells
Malignant tumor cells were harvested from malignant ascites
developed at resistance to pazopanib in this patient as described in the
Methods section. First, we tested if the patient derived tumor cells
were resistant to pazopanib as these cells were cultured at the time of
pazopanib resistance. Using high-throughput 3-dimensional culture
system, we surveyed anti-tumor activity of 13-drug panel (Figure 2A,
left upper panel). We validated the results from 3-dimensional drug
screening results and confirmed with in vitro cell viability assay
(Figure 2A, left lower panel). Based on the initial results from
3-dimentionsal multi-drug testing, we tested the anti-tumor effect of
AZD2014 (TORC1/TORC2 inhibitor), BEZ235 (mTOR/PIK3
inhibitor), lapatinib (HER1, HER2 inhibitor), LEE011 (CDK4
inhibitor), pazopanib which showed IC 50 less than 3.0 μM, in vitro
cell viability assay. In accordance to the results from the
3-dimensional culture assay, we confirmed that the cells were very
sensitive to AZD2014 and BEZ235 while the cells were relatively
resistant to lapatinib, LEE011 and pazopanib. The growth of tumor
cells was significantly reduced by exposure to 1.0 μM AZD2014
compared with control (control versus AZD2014, mean growth =
100.0% vs 16.04%, difference = 83.96%, 95% CI = 70.01% to
97.92%, P = .0435). Similarly, 1.0 μM BEZ235 profoundly
inhibited tumor cell growth in vitro when compared to control
(control versus BEZ235, mean growth = 100.0% vs 7.308%,
difference = 92.69%, 95% CI = 78.87% to 106.5%, P b .0001). In
contrast, despite of the presence of CDK4 amplification (Table 1) in
the patient-derived tumor cells, LEE011 did not considerably inhibit
cell proliferation when compared with control (control versus
LEE011, mean growth = 100.0% vs 80.23%, difference = 19.77%,
95% CI = 1.828% to 37.72%, P = .0377).e of pazopanib treatment in metastatic sarcoma patient.
Figure 2. (A) Using high-throughput 3-dimensional culture system, the anti-tumor activity of 13-drug panel (left upper panel) was tested
using PDC line. The results from 3-dimensional drug screening results were further confirmed with in vitro cell viability assay (left lower
panel). The growth of tumor cells was significantly reduced by exposure to 1.0 μM AZD2014 compared with control (control versus
AZD2014, mean growth = 100.0% vs 16.04%, difference = 83.96%, 95%CI = 70.01% to 97.92%, P= .0435). 1.0 μMBEZ235 profoundly
inhibited tumor cell growth in vitro when compared to control (control versus BEZ235, mean growth = 100.0% vs 7.308%, difference =
92.69%, 95% CI = 78.87% to 106.5%, P b .0001). (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT
signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μMof the indicated drugs for 72 h.
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exposure to each drug. As shown in Figure 2B, we observed that
BEZ235 treatment completely downregulated the AKT phosphory-
lation of tumor cells as well as pmTOR and pERK. AZD2014, a
pharmacologically much “cleaner” TORC1/TORC2 inhibitor, also
down-regulated pmTOR and PI3K but not pAKT. Upon exposure to
AZD2014 and BEZ235, cyclin D1 was virtually undetectable
whereas lapatinib, LEE011 and pazopanib did not have any effect
on its expression. Taken together, upregulation of mTOR/AKT
pathway in pazopanib-resistant tumor derived cells was considerably
inhibited by the treatment of AZD2014 and BEZ235 with
downregulation of AKT pathway (greater extent for BEZ235). In
contrast, LEE011 did not have significant inhibitory effect on
CDK4-amplified sarcoma cells in this particular case.
After successful PDC establishment from malignant ascites, we
implanted these PDCs in NOG mice to evaluate whether PDCs
could be converted into a PDX model. As shown in Figure 3A, the
PDX model could serially passaged for at least 5 times. The histologicTable 1. Genomic profiling of the PDX established from PDC
Genomic alterations by targeted sequencing
SNV/INDEL FGFR1
N457K
FBXW7
P255K
FBXW7
S148T
PIK3R1
M56I
BRCA1
Q309R
CNV CDK4 AMP KIT AMP MDM2 AMP PTEN delexamination demonstrated high grade sarcoma cells. At passage 5,
single cell suspensions from the PDX tumor were generated for
further experiments. The genomic profiling of these cells using
targeted deep sequencing showed FGFR1 (N457K), PIK3R1
(M56I), BRCA1 (Q309R) mutations and CDK4/MDM2/KIT
amplifications and a PTEN deletion (Table 1).
Discussion
In this study, we successfully established patient derived tumor cells
from a metastatic, high grade sarcoma patient who initially responded
to pazopanib but has developed resistance after 6 weeks of treatment.
Using a 3-dimensional high throughput drug screening system and in
vitro cell viability assay, we demonstrated that both an AKT/mTOR
and TORC1/2 inhibitor were effective in inhibiting cell proliferation
of the obtained sarcoma cell line. In contrast, the cells were relatively
resistant to pazopanib, LEE011 or lapatinib. The AKT pathway was
significantly downregulated upon drug treatment with AZD2014 or
BEZ235. Our results suggest that AKT/mTOR inhibition may offer
therapeutic intervention in sarcomas that failed to pazopanib. Except
one case report about reversal of acquired resistance to pazopanib with
mTOR inhibitor [21], no other study has yet been reported
indicating use of BEZ235 or AZD2014 in pazopanib resistant STS.
However, this needs further validation on a larger number of samples
to be considered as a potential therapy.
BEZ235 is a synthetic small molecule belonging to the class of
imidazoquinolines that potently and reversibly inhibits PI3K catalytic
Figure 3. (A) H&E stains of subsequent PDX passages of SMTCA96. The histological architecture is stable over the first four passages:
homogenous growing cells surrounding some small sinusoids could be observed. The picture in passage 4 depicts the edges of the
subcutaneously growing tumor including relevant quantities of surrounding mouse tissue. (B) Growth curves of the PDX model SMTCA
96. As it is frequently observed, the initial establishment and growth of human xenografts in immunocompromised mice takes a longer
time frame than later passages. (C) NMRI nu/nu mice were implanted with fragments of SMTCA 96. Once these pieces engrafted, cohorts
were randomized and treatment with several drugs was started. Pazopanib was administered twice daily at 50 mg/kg/d for two weeks.
Despite this continuous treatment, tumor growth was only slowed down. Once the therapy cycle finished the tumor growth rate was
similar to the control group. This result is in line with both the patient data and the in vitro data from the PDCs were the cells showed still
some effect towards treatment with the inhibitor. In contrast, doxorubicin, another drug registered for sarcoma did not affect tumor
growth in vivo at all (data not shown).
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also inhibits mTOR catalytic activity [22]. Although BEZ235 has
shown promising therapeutic activity in several tumors including
breast cancer, ovarian cancer [23–26] and lymphomas, only a few
reports are available for sarcomas [27,28]. Phase I/II trials with
BEZ235 are still ongoing and results have not been reported yet. In
contrast, AZD2014 is a highly specific mTORC1 and mTORC2
inhibitor [29]. It has displayed activity in models of everolimus
resistance in a long term estrogen deprived background in vitro and in
vivo, suggesting that inhibition of mTORC1 and 2 could be effective
in patients which have become resistant to rapalogues [30]. These
targeted agents can be considered as a potential therapeutic option in
metastatic sarcoma patients who have failed to pazopanib.
We have sequenced the PDX models generated from PDCs with
targeted sequencing and found FGFR1 (N457K), PIK3R1 (M56I),
BRCA1 (Q309R) mutations, which are currently not reported to be
associated with AKT pathway activation. A PTEN deletion was
detected in deep sequencing which may explain sensitivity to PIK3/
mTOR inhibitors. In addition, CDK4 amplification was detected in
this patient. Recently, a phase II trial of the CDK4 inhibitor
PD0332991 in patients with CDK4-amplified liposarcoma have
shown a progression free survival at 12 weeks to be 66% and one
partial response [31]. In our cell line model with CDK4
amplification, the activity of CDK4 inhibitor was modest.
Our study demonstrated that a preclinical model we have
developed can be a useful preclinical screening tool to interrogate
chemosensitivity to targeted agents based on genomic aberrations
[18,32]. The cell-based preclinical model was successfully convertedto PDX animal model as described previously [18]. Although our
results are limited from generalization since it is an observation based
on a single case, our study also demonstrates the potential insight
which can be drawn from a single patient case when combined with
preclinical model and genomic sequencing. Nevertheless, although a
preclinical activity of palifosfamide lysine was very active in
conventional 2-dimensional model of several immortalized cell lines
[33], phase III PICASSO 3 trial which compared palifosfamide/
doxorubicin and doxorubicin/placebo in sarcoma patients have failed
to demonstrate survival benefit [34].
Taken together, the mTOR/AKT pathway in pazopanib-resistant
tumor derived cells was considerably inhibited by the treatment with
AZD2014 or BEZ235 with downregulation of AKT pathway (to a
greater extent for BEZ235). These molecules may be considered as
treatment option for pazopanib-resistant STS patient in the context of
clinical trials.
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